Graft Versus Host Disease (GvHD) Pipeline Analysis 2018 - Focusing On Clinical Trials And Results, Drug Profiling, Patents, Collaborations, And Other Recent Developments
- Published : Mar 2020
- Report Code : KSI061611432
- Pages : 114
Offered with this report
Market Data and Estimates in Excel
2 Months of Post Sale Analyst Support
Requirement Specific Customization
Graft versus Host Disease (GvHD) Pipeline Analysis report covers 55 drugs currently in different phases of development. GvHD arises as the immune mediated disoder when after receiving the transplant, graft reacts against the host cells. In GvHD donated graft (bone marrow or peripheral blood stem cells) view the recipient’s body as foreign, and the donated cells/bone marrow attack the body. GvHD is classified into two types: Acute GvHD and Chronic GvHD. Symptoms of GvHD includes inflammation of skin, Hepatitis, yellow coloration of the skin, Loss of appetite and enteritis.
The report provides Graft versus Host Disease (GvHD) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are AbGenomics International, Inc., Bellicum Pharmaceuticals, Inc., Enlivex Therapeutics ltd, Generon Pharmaceutical Technology, Jazz Pharmaceuticals Inc. and Takeda Oncology among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. AbGenomics International, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Adienne Pharma & Biotech
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Alexion Pharmaeuticals
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Alpine immune Sciences
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Amgen
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Anaptysbio, Inc.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Apceth Biopharma
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Aptevo Therapeutics
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Argenx
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Athersys, Inc.
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Bellicum Pharmaceuticals, Inc.
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Cell2B
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Cellect Biotherapeutics Ltd.
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. CSL Behring
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Cynata Therapeutics
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. CytoDyn, Inc.
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Dr. Falk Pharma GmbH
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. ElsaLys Biotech SA
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. Engene Inc
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.20. Enlivex Therapeutics ltd
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.21. Escape Therapeutics, Inc.
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.22. Fate Therapeutics
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.23. Genentech, Inc.
6.23.1. Introduction
6.23.2. Financials
6.23.3. Products and Services
6.23.4. SWOT
6.24. Generon Pharmaceutical Technology
6.24.1. Introduction
6.24.2. Financials
6.24.3. Products and Services
6.24.4. SWOT
6.25. Gilead
6.25.1. Introduction
6.25.2. Financials
6.25.3. Products and Services
6.25.4. SWOT
6.26. GlaxoSmithKline
6.26.1. Introduction
6.26.2. Financials
6.26.3. Products and Services
6.26.4. SWOT
6.27. Immplacate Health
6.27.1. Introduction
6.27.2. Financials
6.27.3. Products and Services
6.27.4. SWOT
6.28. Inspyr Therapeutics
6.28.1. Introduction
6.28.2. Financials
6.28.3. Products and Services
6.28.4. SWOT
6.29. Janssen Pharmaceuticals
6.29.1. Introduction
6.29.2. Financials
6.29.3. Products and Services
6.29.4. SWOT
6.30. Jazz Pharmaceuticals Inc.
6.30.1. Introduction
6.30.2. Financials
6.30.3. Products and Services
6.30.4. SWOT
6.31. Kadmon Holdings, Inc.
6.31.1. Introduction
6.31.2. Financials
6.31.3. Products and Services
6.31.4. SWOT
6.32. Kalytera Therapeutics, Inc.
6.32.1. Introduction
6.32.2. Financials
6.32.3. Products and Services
6.32.4. SWOT
6.33. Kamada, Ltd.
6.33.1. Introduction
6.33.2. Financials
6.33.3. Products and Services
6.33.4. SWOT
6.34. Kiadis Pharma
6.34.1. Introduction
6.34.2. Financials
6.34.3. Products and Services
6.34.4. SWOT
6.35. Kymab
6.35.1. Introduction
6.35.2. Financials
6.35.3. Products and Services
6.35.4. SWOT
6.36. MaaT Pharma
6.36.1. Introduction
6.36.2. Financials
6.36.3. Products and Services
6.36.4. SWOT
6.37. Mallinckrodt Pharmaceuticals
6.37.1. Introduction
6.37.2. Financials
6.37.3. Products and Services
6.37.4. SWOT
6.38. Mesoblast Ltd
6.38.1. Introduction
6.38.2. Financials
6.38.3. Products and Services
6.38.4. SWOT
6.39. MolMed S.p.A.
6.39.1. Introduction
6.39.2. Financials
6.39.3. Products and Services
6.39.4. SWOT
6.40. NapaJen Pharma, Inc.
6.40.1. Introduction
6.40.2. Financials
6.40.3. Products and Services
6.40.4. SWOT
6.41. Neovii Biotech
6.41.1. Introduction
6.41.2. Financials
6.41.3. Products and Services
6.41.4. SWOT
6.42. Novartis
6.42.1. Introduction
6.42.2. Financials
6.42.3. Products and Services
6.42.4. SWOT
6.43. Ocugen, Inc.
6.43.1. Introduction
6.43.2. Financials
6.43.3. Products and Services
6.43.4. SWOT
6.44. OncoImmune
6.44.1. Introduction
6.44.2. Financials
6.44.3. Products and Services
6.44.4. SWOT
6.45. Osiris
6.45.1. Introduction
6.45.2. Financials
6.45.3. Products and Services
6.45.4. SWOT
6.46. Regimmune Co., Ltd.
6.46.1. Introduction
6.46.2. Financials
6.46.3. Products and Services
6.46.4. SWOT
6.47. Seattle Genetics, Inc.
6.47.1. Introduction
6.47.2. Financials
6.47.3. Products and Services
6.47.4. SWOT
6.48. Seres Therapeutics
6.48.1. Introduction
6.48.2. Financials
6.48.3. Products and Services
6.48.4. SWOT
6.49. Takeda Oncology
6.49.1. Introduction
6.49.2. Financials
6.49.3. Products and Services
6.49.4. SWOT
6.50. Targazyme, Inc.
6.50.1. Introduction
6.50.2. Financials
6.50.3. Products and Services
6.50.4. SWOT
6.51. TxCell
6.51.1. Introduction
6.51.2. Financials
6.51.3. Products and Services
6.51.4. SWOT
6.52. Vault Pharma
6.52.1. Introduction
6.52.2. Financials
6.52.3. Products and Services
6.52.4. SWOT
6.53. Xenikos B.V.
6.53.1. Introduction
6.53.2. Financials
6.53.3. Products and Services
6.53.4. SWOT
6.54. XL-protein GmbH
6.54.1. Introduction
6.54.2. Financials
6.54.3. Products and Services
6.54.4. SWOT
6.55. Zai Lab
6.55.1. Introduction
6.55.2. Financials
6.55.3. Products and Services
6.55.4. SWOT
List of Tables
List of Figures
Adienne Pharma & Biotech
Alexion Pharmaeuticals
Alpine immune Sciences
Amgen
Anaptysbio, Inc.
Apceth Biopharma
Aptevo Therapeutics
Argenx
Athersys, Inc.
Bellicum Pharmaceuticals, Inc.
Cell2B
Cellect Biotherapeutics Ltd.
CSL Behring
Cynata Therapeutics
CytoDyn, Inc.
Dr. Falk Pharma GmbH
ElsaLys Biotech SA
Engene Inc
Enlivex Therapeutics ltd
Escape Therapeutics, Inc.
Fate Therapeutics
Genentech, Inc.
Generon Pharmaceutical Technology
Gilead
GlaxoSmithKline
Immplacate Health
Inspyr Therapeutics
Janssen Pharmaceuticals
Jazz Pharmaceuticals Inc.
Kadmon Holdings, Inc.
Kalytera Therapeutics, Inc.
Kamada, Ltd.
Kiadis Pharma
Kymab
MaaT Pharma
Mallinckrodt Pharmaceuticals
Mesoblast Ltd
MolMed S.p.A.
NapaJen Pharma, Inc.
Neovii Biotech
Novartis
Ocugen, Inc.
OncoImmune
Osiris
Regimmune Co., Ltd.
Seattle Genetics, Inc.
Seres Therapeutics
Takeda Oncology
Targazyme, Inc.
TxCell
Vault Pharma
Xenikos B.V.
XL-protein GmbH
Zai Lab
Related Reports
| Report Name | Published Month | Get Sample PDF |
|---|---|---|
| Connected Agriculture Market Size & Share: Report, 2021-2026 | Sep 2021 | |
| Pyrometer Market Size, Share & Trends: Industry Report, 2021-2026 | Jun 2021 | |
| Radiotherapy Market Size & Share: Industry Report, 2021-2026 | Jul 2021 | |
| Data Center Colocation Market Size & Share: Report, 2023 - 2028 | Jun 2023 | |
| Industrial Enzymes Market Share & Trends: Report, 2024-2029 | Mar 2024 |